Abstract
The effect of treatment with melatonin was investigated in a rat model of Alzheimer’s disease (AD) involving a single intra-hippocampal injection of amyloid peptide Aβ1-42. Thirty days after this injection immunohistochemical analysis revealed significant increases of both S-100β and NFκB in cortex and hippocampus of treated animals. Levels of synaptophysin were depressed following treatment and this was confirmed by Western blotting. Histopathological studies revealed a diminution of neuronal cell number in the CA3 area of the hippocampus. Behaviorally, the rate of learning escape from electroshock using a maze box was diminished in Aβ-treated mice. Another group of Aβ treated also received an oral gavage of 0.5 mg/kg melatonin on each of the 30 days between Aβ treatment and sacrifice. The effect of this repeated melatonin exposure was to reverse Aβ-induced changes in CA3 cell number and S-100 levels. The increased cerebral content of NF-κB and the behavioral changes caused by Aβ treatment were partially reversed by melatonin. However, melatonin administration had no effect on the reduced level of synaptophysin in Aβ-treated mice. Overall, these findings suggest that melatonin may exert a potentially beneficial effect upon the progression of AD.
Keywords: Alzheimer's disease, amyloid, hippocampus, learning, melatonin, NF-κB.
Current Aging Science
Title:Melatonin Decreases Levels of S100β and NFκB, Increases Levels of Synaptophysinina Rat Model of Alzheimer's Disease
Volume: 6 Issue: 2
Author(s): Zhou Jun, Zhou Li, Wang Fang, Yang Fengzhen, Wen Puyuan, Li Wenwen, Song Zhi and Stephen C. Bondy
Affiliation:
Keywords: Alzheimer's disease, amyloid, hippocampus, learning, melatonin, NF-κB.
Abstract: The effect of treatment with melatonin was investigated in a rat model of Alzheimer’s disease (AD) involving a single intra-hippocampal injection of amyloid peptide Aβ1-42. Thirty days after this injection immunohistochemical analysis revealed significant increases of both S-100β and NFκB in cortex and hippocampus of treated animals. Levels of synaptophysin were depressed following treatment and this was confirmed by Western blotting. Histopathological studies revealed a diminution of neuronal cell number in the CA3 area of the hippocampus. Behaviorally, the rate of learning escape from electroshock using a maze box was diminished in Aβ-treated mice. Another group of Aβ treated also received an oral gavage of 0.5 mg/kg melatonin on each of the 30 days between Aβ treatment and sacrifice. The effect of this repeated melatonin exposure was to reverse Aβ-induced changes in CA3 cell number and S-100 levels. The increased cerebral content of NF-κB and the behavioral changes caused by Aβ treatment were partially reversed by melatonin. However, melatonin administration had no effect on the reduced level of synaptophysin in Aβ-treated mice. Overall, these findings suggest that melatonin may exert a potentially beneficial effect upon the progression of AD.
Export Options
About this article
Cite this article as:
Jun Zhou, Li Zhou, Fang Wang, Fengzhen Yang, Puyuan Wen, Wenwen Li, Zhi Song and Bondy C. Stephen, Melatonin Decreases Levels of S100β and NFκB, Increases Levels of Synaptophysinina Rat Model of Alzheimer's Disease, Current Aging Science 2013; 6 (2) . https://dx.doi.org/10.2174/18746098112059990005
DOI https://dx.doi.org/10.2174/18746098112059990005 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serum Starvation Induces BACE1 Processing and Secretion
Current Alzheimer Research CD248: Reviewing its Role in Health and Disease
Current Drug Targets Cell Death in Mammalian Development
Current Pharmaceutical Design Recent Developments on Multi-Target-Directed Tacrines for Alzheimer's Disease. I. The Pyranotacrines
Current Topics in Medicinal Chemistry Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress
Current Proteomics Biological Targets of Antitumor Indolocarbazoles Bearing a Sugar Moiety
Current Medicinal Chemistry - Anti-Cancer Agents BRI2 Interacts with BACE1 and Regulates Its Cellular Levels by Promoting its Degradation and Reducing Its mRNA Levels
Current Alzheimer Research Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Current Vascular Pharmacology Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology Perspectives on Medicinal Properties of Mangiferin
Mini-Reviews in Medicinal Chemistry Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma <i>via Akt</i> Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies
Current Pharmaceutical Design Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Anti-Cancer Agents in Medicinal Chemistry Tumor-Targeted Inhibition by a Novel Strategy - Mimoretrovirus Expressing siRNA Targeting the Pokemon Gene
Current Cancer Drug Targets Functions of S100 Proteins
Current Molecular Medicine Observations on the Use of the Avian Chorioallantoic Membrane (CAM) Model in Investigations into Angiogenesis
Current Drug Targets - Cardiovascular & Hematological Disorders